Medigene AG Stock price

Equities

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Market Closed - Xetra 12:36:02 2024-03-28 pm EDT After market 04:57:47 pm
2.11 EUR -0.47% Intraday chart for Medigene AG 2.12 +0.47%
Sales 2023 * 5.5M 5.93M Sales 2024 * 11.5M 12.4M Capitalization 52.07M 56.14M
Net income 2023 * -18M -19.41M Net income 2024 * -12M -12.94M EV / Sales 2023 * 9.1 x
Net cash position 2023 * 2M 2.16M Net Debt 2024 * 17M 18.33M EV / Sales 2024 * 6.01 x
P/E ratio 2023 *
-2.75 x
P/E ratio 2024 *
-5.37 x
Employees 87
Yield 2023 *
-
Yield 2024 *
-
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
Medigene Ag Provides Earnings Guidance for 2024 CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023 CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023 CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types CI
Medigene AG Provides Revenue Guidance for 2023 CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Medigene AG Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies CI
Transcript : Medigene AG - Special Call
Medigene AG Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs CI
Medigene AG Presents the Web Tool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy CI
More news
1 day+4.25%
1 week+9.00%
Current month+48.81%
1 month+50.34%
3 months+51.92%
6 months+23.16%
Current year+42.95%
More quotes
1 week
1.92
Extreme 1.92
2.90
1 month
1.45
Extreme 1.45
2.90
Current year
1.39
Extreme 1.385
2.90
1 year
1.35
Extreme 1.35
2.90
3 years
1.35
Extreme 1.35
4.59
5 years
1.35
Extreme 1.35
10.85
10 years
1.35
Extreme 1.35
19.42
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 22-07-24
Chief Tech/Sci/R&D Officer - 14-04-30
Chief Tech/Sci/R&D Officer - 21-02-28
Members of the board TitleAgeSince
Director/Board Member 66 16-08-11
Director/Board Member 62 18-05-14
Director/Board Member 68 20-12-15
More insiders
Date Price Change Volume
24-03-28 2.11 -0.47% 123 601
24-03-27 2.12 -10.17% 56,527
24-03-26 2.36 -13.24% 171,348
24-03-25 2.72 +15.74% 234,877
24-03-22 2.35 +17.50% 191,378

Delayed Quote Xetra, March 28, 2024 at 05:36 am EDT

More quotes
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.12 EUR
Average target price
2.675 EUR
Spread / Average Target
+26.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Medigene AG - Xetra